ReviewNature reviews. Urology2011
Urothelial carcinoma of the bladder: definition, treatment and future efforts.
Review in Nature reviews. Urology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Rs-10889677 variant in interleukin-23 receptor may contribute to creating an inflammatory milieu more susceptible to bladder tumourigenesis: report and meta-analysis.Immunogenetics · 2021Pooled it
- Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas.Journal of the National Cancer Institute · 2018Pooled it
- Do histological variants in urothelial carcinoma of the bladder portend poor prognosis? A systematic review and meta-analysis.Oncotarget · 2017Pooled it
- A case report on silent clear cell renal cell carcinoma with intraluminal ureteric extension: a pattern beyond conventional AJCC staging.Annals of medicine and surgery (2012) · 2026Article
- Evaluation of human epidermal growth factor receptor 2 (HER2)-related genes revealed that HER2-antibody-drug conjugate (ADC) drugs confer clinical benefits to Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer patients.Translational andrology and urology · 2026Article
- Ro 31-8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo.FEBS open bio · 2025Article
- PKIB facilitates bladder cancer proliferation and metastasis through mediation of HSP27 phosphorylation by PKA.Cell death & disease · 2025Article
- The role of circular RNA targeting IGF2BPs in cancer-a potential target for cancer therapy.Journal of molecular medicine (Berlin, Germany) · 2024Review
- Relapse and Survival in Bladder Cancer Patients Undergoing microRNA-129 and microRNA-145 Assays.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Article
- Tailoring treatment for elderly bladder cancer: a case report of personalized management of high-grade urothelial carcinoma with papillary features.Frontiers in oncology · 2024Article
- A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ.Nature communications · 2023Article
- Deregulated Expression ofInternational journal of molecular sciences · 2023Article
- Comprehensive Analysis of the Expression, Prognosis, and Biological Significance of PLOD Family in Bladder Cancer.International journal of general medicine · 2023Article
- Epigenetic regulation ofMolecular therapy. Nucleic acids · 2022Article
- Higher Expression of Annexin A2 in Metastatic Bladder Urothelial Carcinoma Promotes Migration and Invasion.Cancers · 2022Article
- Integrated Analysis of the Fecal Metagenome and Metabolome in Bladder Cancer in a Chinese Population.Genes · 2022Article
- A Novel tiRNA-Gly-GCC-1 Promotes Progression of Urothelial Bladder Carcinoma and Directly Targets TLR4.Cancers · 2022Article
- Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer.Cancers · 2022Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The identification of patients with high-risk bladder cancer is important for the timely and appropriate treatment of this lethal disease. The understanding of the natural history of bladder cancer has improved; however, the criteria used to define high-risk disease and the relevant treatment strategies have remained the same for the past several decades, despite multiple large, randomized, prospective clinical trials that have evaluated the use of intravesical, surgical and systemic therapies. The genetic signature of high-risk bladder cancer has been a focus of investigation and has led to the discovery of potential molecular targets for disease identification, risk stratification and therapy. These advances, combined with a comprehensive risk assessment profile that incorporates available pathological and clinical characteristics, might improve the diagnosis and treatment of patients with bladder cancer.
Indexed as
Identifiers
21989305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.